CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com. Investor Relations Contact:Shai Biran, PhDSpero...

Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 PRISM wet AMD Phase 2b 2-year data expected in mid-2026 and SPECTRA DME trial 2-year data in H2 2026 4D-150 DME global Phase 3 trial initiation expected in Q3 2026 $514 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full...

4Q25: Ending the year with strong growth momentum, with broad-based acceleration across key metrics. TPV at an all-time quarterly high of US$13.1 billion, growing 70% year-over-year, the fifth straight quarter above 50% year-over-year. Revenue up +65% year-over-year reaching US$338 million for the quarter. Gross profit reached US$116 million, up +38% year-over-year. Adjusted EBITDA up +38% year-over-year, representing 68% of gross profit, underscoring best-in-class operating leverage and disciplined cost management. Net income growth at +87% year-over-year. Solid free cash generation, with adjusted free cash flow to net income ratio at 117%. 2025: Demonstrated the scale of the emerging markets opportunity: record TPV of US$41 billion, up 60% year-over-year with revenue crossing the $1 billion milestone for the first time. Gross profit...

Q4 Net Sales Increase of 24.3% to $1.73 Billion; Q4 Comparable Sales Increase of 15.4% FY 2025 Net Sales Increase of 22.9% to $4.76 Billion; FY 2025 Comparable Sales Increase of 12.8% Q4 GAAP Diluted EPS Increase of 26.3% to $4.28, Q4 Adjusted Diluted EPS Increase of 23.9% to $4.31 FY 2025 GAAP Diluted EPS Increase of 40.7% to $6.47, FY 2025 Adjusted Diluted EPS Increase of 32.3% to $6.67 Provides First Quarter and Fiscal 2026 Outlook PHILADELPHIA, PA, March 18, 2026 (GLOBE NEWSWIRE) — Five Below, Inc. (NASDAQ: FIVE) today announced financial results for the fourth quarter and full year of fiscal 2025 ended January 31, 2026. For the fourth quarter ended January 31, 2026:Net sales increased by 24.3% to $1.73 billion from $1.39 billion in the fourth quarter of fiscal 2024; comparable sales increased by 15.4%. The Company opened...

SALT LAKE CITY, March 18, 2026 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, reports its financial results for the year ended December 31, 2025. Fourth Quarter and Full-Year 2025 Financial Highlights Fourth quarter 2025 total revenue was $26.2 million, representing an increase of 1,985% or $24.9 million from $1.3 million in the prior year. Fourth quarter 2025 total revenue increased sequentially by 172% to $26.2 million. Full-year 2025 total revenue was $40.7 million, representing an increase of 161% or $25.1 million from $15.6 million in the prior year. Business HighlightsSecured new orders for Black Widow™ drones from an Asia-Pacific ally. This is...

DENVER, March 18, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress.Date/Time: Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT   Webcast: The live webcast and replay can be found here.   Register for the call: Preregistration is required to attend the live call and can be accessed here. A pin code and dial in number will be provided with registration.   A replay of the call will be available after...

Record Full Year Revenues, Processing Volume (up 19%) and Transactions Processed (up 30%) SAN ANTONIO, March 18, 2026 (GLOBE NEWSWIRE) — Usio, Inc. (“Usio” or the “Company”) (Nasdaq: USIO), a leading Fintech company that operates a full stack of integrated, cloud-based electronic payment and embedded financial solutions, today announced financial results for the fourth quarter and year ended December 31, 2025. Louis Hoch, Chairman and Chief Executive Officer of Usio, said, “I am pleased to report another year of positive Adjusted EBITDA1 and Cash Flow from Operations on solid revenue growth. In addition, we increased total processing volume to $8.4 billion, up 19% compared to 2024. As anticipated, the second half of the year was much improved from the first half, especially the fourth quarter, where...

Record results and outlook reflect strategic value of memory in AI era BOISE, Idaho, March 18, 2026 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) today announced results for its second quarter of fiscal 2026, which ended February 26, 2026. Fiscal Q2 2026 highlightsRevenue of $23.86 billion versus $13.64 billion for the prior quarter and $8.05 billion for the same period last year GAAP net income of $13.79 billion, or $12.07 per diluted share Non-GAAP net income of $14.02 billion, or $12.20 per diluted share Operating cash flow of $11.90 billion versus $8.41 billion for the prior quarter and $3.94 billion for the same period last year“Micron set new records across revenue, gross margin, EPS, and free cash flow in fiscal Q2, driven by a strong demand environment, tight industry supply, and our strong execution,...

MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 HighlightsTotal revenue of $49.1 million, a 40% increase year-over-year Gross margin of 79.5%, non-GAAP gross margin of 79.9% Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 million U.S. installed base of 1,465 accounts as of December 31, 2025 U.S. Plaque installed base of 489 accounts as of December 31, 2025 Aetna began coverage of Heartflow Plaque Analysis, bringing total U.S. covered lives for Plaque to approximately 75%2026 Annual GuidanceTotal revenue of $218 million to $222 million (approximately 24% to 26% growth year-over-year) Non-GAAP...

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint Presented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASN Ended 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported...